Champion swimmer Archie Goodburn's remarkable story is a testament to the human spirit, but it also highlights the urgent need for increased investment in brain cancer research. At just 24 years old, Goodburn has already faced the daunting prospect of a rare and inoperable form of brain cancer – a condition that has left him questioning his future.
Goodburn's journey took an unexpected turn two years ago when he began experiencing alarming symptoms during training. Weakness, numbness, and intense fear prompted a diagnosis of three oligodendrogliomas, a rare type of brain tumour accounting for approximately 3% of all brain cancer diagnoses. The prospect of immediate chemotherapy and radiotherapy would have been devastating, affecting his cognitive abilities and academic pursuits.
A turning point came with access to Vorasidenib, a breakthrough treatment that halted the growth of his tumours. This innovative drug gave Goodburn a reprieve, allowing him to return to competitive swimming – including breaking a Scottish record and preparing for the Commonwealth Games. However, he stresses that Vorasidenib offers only a temporary solution, with trial data suggesting it may provide around four years. Goodburn remains adamant that sustained progress is essential, vowing to continue his campaign for better treatments.
Tragically, brain cancer is still the leading cancer killer for children and adults under 40 in the UK. Despite this stark reality, research funding has historically been woefully inadequate – accounting for just 1% of the government's cancer research budget since 2002. Goodburn highlights a critical "translational gap" between promising early-stage research and accessible clinical trials. This gap is attributed to a fragmented and risk-averse funding system, described by the all-party parliamentary group on brain tumours as a "valley of death."
Goodburn and the Brain Cancer Justice campaign are now urging the government to release the remaining £40 million pledged in 2018 for brain cancer research. They demand that these funds be allocated directly to frontline scientists, alongside other measures including the appointment of a dedicated brain cancer lead within the government. The team also wants increased genomic sequencing for patients at diagnosis and the establishment of a "right to try" for potentially life-saving treatments.
The Department of Health and Social Care has acknowledged the need for more research, committing to improving patient access to innovative medicines. However, Goodburn's impassioned plea serves as a stark reminder that progress remains slow – leaving many patients without hope or access to effective treatment. It is imperative that the government acts swiftly to address these concerns and provide the necessary support for those fighting this devastating condition.